We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Gastric Cancer Treatments and Survival Trends in the United States.
- Authors
Stahl, Kelly A.; Olecki, Elizabeth J.; Dixon, Matthew E.; Peng, June S.; Torres, Madeline B.; Gusani, Niraj J.; Chan Shen
- Abstract
We also found that three-year OS significantly improved for patients with stage I and stage II/III disease that received stage specific guideline concordant care compared to patients that did not receive stage specific guideline concordant. We found that for both stage I and stage II/III disease a predictor of the receipt of non-guideline concordant care was patient age > 70 years old (stage I OR 2.9, CI 2.4-3.4, p-value < 0.001; stage II/III OR 5.0, CI 4.6-5.5, p value < 0.001). Of the 40,216 patients with stage II/III disease, 20,450 or 51%, received stage II/III guideline concordant care, defined here as surgery and chemotherapy, surgery and radiation or trimodality therapy [8]. We also found that three-year OS significantly improved for patients with stage I and stage II/III disease that received stage specific guideline concordant care compared to patients that did not receive stage specific guideline concordant.
- Subjects
STOMACH cancer; LYMPHADENECTOMY; CANCER treatment; CHEMORADIOTHERAPY; MUCINOUS adenocarcinoma
- Publication
Current Oncology, 2021, Vol 28, Issue 1, p138
- ISSN
1198-0052
- Publication type
Article
- DOI
10.3390/curroncol28010017